Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Teva Pharmaceuticals announced the launch of Capecitabine Tablets, the generic equivalent to Genentech’s Xeloda. Teva is the first company to receive approval for its ANDA for Capecitabine Tablets.
Xeloda is a fluoropyrimidine indicated for metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel when further anthracycline therapy is not indicated; and with docetaxel for metastatic breast cancer after failure of prior anthracycline-containing regimen.
RELATED: Oncology Resource Center
Capecitabine is available in 150mg and 500mg strength tablets.
For more information call (888) 838-2872 or visit TevaGenerics.com.
Related Content
